Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces it will present a poster entitled ‘AVA6000, a novel precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage’, at the American Association for Cancer Research (AACR) 2022 Annual Meeting, taking place at Ernest N. Morial Convention Center, New Orleans, Louisana between 8-13 April.
The poster describes the pre-clinical rationale for the company’s leading oncology candidate, AVA6000, a FAP ( fibroblast activation protein ?) activated doxorubicin therapeutic. AVA6000 utilises Avacta’s pre|CISION™ platform to improve the safety and therapeutic index of doxorubicin. AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated FAP which is in high concentration in many solid tumours compared with healthy tissues. The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression. A first-in-human Phase I clinical trial (ALS-6000-101) has been initiated in the UK in a broad spectrum of high FAP expressing tumours.
Poster presentation Title: AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage.
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Targets
Session Date and Time: Monday Apr 11, 2022 1:30 PM – 5:00 PM CT
Location: New Orleans Convention Center, Exhibit Halls D-H
Abstract Number: #1815
Presenter: Fiona McLaughlin, PhD, Chief Scientific Officer and Neil Bell, Chief Development Officer, Avacta Life Sciences Ltd.
The abstract is available via the AACR annual meeting website, here: https://www.aacr.org/meeting/aacr-annual-meeting-2022/abstracts/
Copies of the poster will be available on Avacta’s website following the conference at: https://avacta.com/investors/documents-presentations/